---
document_datetime: 2026-01-14 11:07:40
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nemluvio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nemluvio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.912735
conversion_datetime: 2026-01-17 23:27:01.237336
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Nemluvio

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Application number       | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR/EMA/PSUR/0000282252 | In view of available data on Bullous Pemphigoid (BP) from the literature, spontaneous reports and clinical trial(s), including • at least 12 possible cases of BP with close temporal relationship, confirmed BP diagnosis and recovery (with treatment) following withdrawal; •and 2 probable literature cases with a close temporal relationship, confirmed BP diagnosis and recovery (with treatment ) following withdrawal, without reoccurrence of BP after withdrawal, supportive anti-BP 180 data and excluding the influence of most confounding factors; • although the potential mechanism of the AE remains to be elucidated; the PRAC considers a causal relationship between nemolizumab and Bullous Pemphigoid is at least a reasonable possibility. The PRAC concluded that the product information of products containing nemolizumab should be amended accordingly. | 13/11/2025                          | 08/01/2026                                  | SmPC and PL                      | Variation |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000310765   | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                             | 10/11/2025   | 08/01/2026   | Annex II and PL   |                   |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-------------------|
| Variation type IA /                        | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 20/10/2025   | N/A          |                   | EMA/VR/0000306885 |
| Variation type IB / EMA/VR/0000296279      | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.c Deletion of a                                                                                                                                                                                                                                                                                                                                                                                                              | 16/10/2025   | N/A          |                   |                   |

<div style=\"page-break-after: always\"></div>

|                                       | non-significant in-process test - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted          |            |            |                        |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type IB / EMA/VR/0000281966 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                               | 29/07/2025 | 08/01/2026 | SmPC                   |
| Variation type IA / EMA/VR/0000288003 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted | 25/07/2025 | N/A        |                        |
| Variation type IB / EMA/VR/0000278836 | C.I.7 Deletion of: - C.I.7.a a pharmaceutical form - Accepted C.I.7.a - To delete the pharmaceutical form powder and solvent for solution for injection in pre-filled syringe from the Nemluvio marketing authorisation (EU/1/24/1901/004). The Annexes are           | 17/07/2025 | 08/01/2026 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                          | updated accordingly. Additionally, the MAH took the opportunity to amend section 4.8 of the SmPC with information on worsening of asthma and superficial fungal infections, as requested by the Rapporteur, and made editorial changes to the PI in DK, DE, FI, IT, NO, PL, and SE to implement changes that were not implemented during previous linguistic review and to correct for typographical errors. Furthermore, the MAH took the opportunity to update the list of local representatives for BG, CZ, EE, GR, FR, HR, CY, LV, LT, HU, MT, RO, SI and SK in section 6 of the PL.   |            |     |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA_IN / EMA/VR/0000253858 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                                                                                                                                                                                                             | 05/03/2025 | N/A |